Suboxone.com - Treating Opioid Dependence

The requested information is provided in Portable Document Format (PDF). To view and print this document you'll need to install a copy of the free Adobe® Acrobat® Reader®. If you already have Adobe Acrobat Reader installed click "View PDF" below. If you need the Acrobat Reader you can download it from the Adobe Acrobat Reader Download page.

You are leaving Suboxone.com. Links are provided as a public service and for informational purposes only. No endorsement is made or implied. Clicking on "Continue" will take you to a website that is outside the control of Reckitt Benckiser Pharmaceuticals. You are solely responsible for your interactions with such websites.

Links are provided as a public service and for informational purposes only.

IMPORTANT INFORMATION:

On December 8, 2006, Federal legislation was passed allowing physicians to treat up to 100 opioid dependent patients with Suboxone at any given time—a significant increase from the previous limit of 30 patients.

If you can read this, then your browser cannot interpret Javascript. To take full advantage of what this website has to offer, please make sure that you have Javascript enabled in your browser preferences, or update to a browser that supports Javascript. Thank you.

Prescribing Information -- Site Map

SUBOXONE Webinars

Video presentations addressing the most common questions healthcare professionals have when starting to prescribe SUBOXONE

SUBOXONE Practice Management Tool Kit

Information about treating opioid dependence, including patient management, preparing your practice, creating a referral network, and more.

Treating Opioid Dependence

Opioid dependence in the United States is growing at unprecedented rates, yet more than 75% of this population is untreated.¹

This opioid-dependence treatment gap is the result of several factors. Among them are insufficient treatment resources, limited access to treatment, the stigma associated with treatment, and under-diagnosis of the condition.¹

The government's recognition of the urgent need for treatments that could transcend these obstacles was a primary reason behind the Drug Addiction Treatment Act of 2000 (DATA 2000), which opened the door for office-based treatment of opioid dependence.

The first medications approved under this act were SUBUTEX® (buprenorphine HCl sublingual tablets) and SUBOXONE.

By improving the convenience, privacy, and availability of opioid-dependence treatment, office-based treatment with SUBOXONE has the potential to help thousands receive the care they need.

This section covers a range of topics related to the treatment of opioid dependence, including identifying the condition, approaching patients, and describing what office-based treatment is actually like.

Helping healthcare professionals to become more familiar with opioid dependence and its treatment is the first step in bringing this care back into the medical mainstream and ensuring that every patient who wants help for dependence can receive it.

Reference

1.	Center for Substance Abuse Treatment (CSAT). Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, Md: Substance Abuse and Mental Health Services Administration, 2004.